Navigation Links
Newest HIV drugs should be used with FUZEON(R)

Data presented at IAS build a compelling case for FUZEON (enfuvirtide, formerly known as T-20) to be combined with the newest drugs to give patients facing resistance their best chance of achieving undetectable viral load ?the optimal treatment goal for all people living with HIV.

"Undetectable viral load should be the ultimate treatment goal for all triple-class experienced patients. FUZEON combined with the latest drugs now makes this much more achievable," explained Dr Mike Youle the Royal Free Hospital, London. "We are seeing a consistent FUZEON effect with these new drugs and I believe these data must change the way we manage triple class experienced patients facing HIV resistance and failing to reach undetectable viral load."

Studies presented this week show that when FUZEON was given in combination with the novel HIV medication, tipranavir, an impressive 70% of FUZEON naïve patients achieved a ten-fold reduction in their viral load and furthermore they also had double the increase in immune cell count1, compared to patients receiving tipranavir/r without FUZEON.

This adds to the growing body of evidence for the powerful "FUZEON effect" which has been seen across the RESIST 1 & 2, POWER 1 & 2 and TORO 1 & 2 studies, where adding FUZEON was seen to almost double the number of patients reaching undetectable, when combined with one of the latest boosted PIs such as lopinavir/r, tipranavir/r or TMC 114/r.

Doctors underestimate significant "FUZEON effect"

Surprisingly, of the 560 doctors surveyed onsite this week at the IAS conference, three quarters (75%) underestimated the "FUZEON effect" seen in both RESIST2 and POWER3 studies.

Latest data adds to growing Body of Evidence ?Latest Boosted Protease Inhibitors (lopinavir/r, tipranavir/r and TMC 114/r) all work best in combination with FUZEON

RESIST Phase III tipranavir trials
Over 24 weeks, almost double the proportion of patients who received FUZEON plus tipranavir/r showed a 90% drop in viral load compared with patients not receiving FUZEON

POWER Phase II TMC114 dosing trials
Over 24 weeks in the combined TMC114 trials, almost double the proportion of patients who received FUZEON plus TMC114/r achieved a viral load below 50 copies/ml compared with patients not receiving FUZEON A remarkable 67% of the patients receiving FUZEON plus TMC114/r reached an undetectable viral load

TORO Phase III FUZEON trials
Over 24 weeks, double the proportion of patients who received FUZEON plus lopinavir/r achieved an undetectable viral load (<50 copies/ml) compared with patients not receiving FUZEON

Collectively the data from all six studies, in over 2,500 patients, establish a new paradigm in the management of triple class-experienced patients.

Why FUZEON is effective in face of HIV resistance

FUZEON is still the first and only anti-retroviral drug to work outside the human immune cell (CD4), blocking the HIV virus from entering. All other currently available HIV drugs fight the HIV virus once it has entered the cell. FUZEON's unique mode of action means that FUZEON has no cross-resistance with currently available drugs and that it is an effective treatment, in combination with other anti–HIV drugs, for patients facing resistance.

New combination improves quality of life

Spike, a 48 year old person living with HIV from London, whose blood levels of HIV reached undetectable within six months of taking FUZEON and boosted tipranavir and has remained undetectable ever since, explains "This new combination of treatments has really improved my quality of life. Getting back to undetectable and seeing my CD4 count increase from 20 to 268 has changed my outlook on life. I believe I can plan for the future, which I didn't even consider doing before starting this regimen. I have much more energy now than I had before, which is exhilarating since I have been held b ack for so long." Spike has been living with HIV since it was detected in his body in 1986 and works as a freelance designer and night-club promoter.

The use of FUZEON is continuing to grow, despite initial reluctance from patients and physicians to using an injection, and more patients are now successfully starting and remaining on treatment. Roche continues to roll out educational initiatives to support patients and physicians with the administration and use of FUZEON.


'"/>

Source:Ketchum


Related biology news :

1. Molecular machine may lead to new drugs to combat human diseases
2. Researchers identify target for cancer drugs
3. MetaChip provides quick, efficient toxicity screening of potential drugs
4. Newly discovered pathway might help in design of cancer drugs
5. UNC launches study of liver injury caused by drugs
6. Findings have implications for tracking disease, drugs at the molecular level
7. Future diabetes drugs may target new protein interaction
8. UCLA study assesses cost-effectiveness of Hepatitis B drugs
9. Sponges as drugs
10. Recombinant DNA technology may enable oral, rather than injectable, delivery of protein drugs
11. FDA approves more generic AIDS drugs
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:3/30/2017)... LOS ANGELES , March 30, 2017  On ... Hack the Genome hackathon at ... This exciting two-day competition will focus on developing health ... experience. Hack the Genome is ... has been tremendous. The world,s largest companies in the ...
(Date:3/30/2017)... 2017 Trends, opportunities and forecast in this ... technology (fingerprint, AFIS, iris recognition, facial recognition, hand geometry, ... end use industry (government and law enforcement, commercial and ... and others), and by region ( North America ... Asia Pacific , and the Rest of the ...
(Date:3/28/2017)... The report "Video Surveillance Market ... Storage Devices), Software (Video Analytics, VMS), and Service (VSaaS, ... to 2022", published by MarketsandMarkets, the market was valued ... to reach USD 75.64 Billion by 2022, at a ... year considered for the study is 2016 and the ...
Breaking Biology News(10 mins):
(Date:6/19/2017)... King of Prussia, PA (PRWEB) , ... June 19, 2017 , ... ... by life sciences companies for over 50 years. One of the biggest challenges faced ... environment. Joining the firm’s regulatory affairs services team is Kati Abraham , who ...
(Date:6/16/2017)... ... June 16, 2017 , ... Cambridge Semantics ... that its Anzo Smart Data Lake® (Anzo SDL) solution was named a ... 2017 Software & Information Industry Association (SIIA) CODiE Awards. , Finalists represent ...
(Date:6/15/2017)... ... June 15, 2017 , ... Cybrexa Therapeutics, ... B round of financing in the amount of $6 million. An investment vehicle ... in the round. , The Series B funding will enable Cybrexa to complete ...
(Date:6/15/2017)... Wash. (PRWEB) , ... June 15, 2017 , ... ... global business director for DuPont Biofuels, will be speaking at Bloomberg’s 2017 ... Koninckx will join other leading environmental and sustainability officials on a panel titled ...
Breaking Biology Technology: